Founded in 2018, Enveda Biosciences operates in ai drug discovery. Its most recent disclosed valuation is $650M. The stock is not listed on any public market.
1 valuation. The latest, $650M post-money, was set by the Series C in Nov 2024.
Premji InvestLEADKKinnevikLEADFFPV
MicrosoftDDimension
Lux CapitalPremji InvestKinnevikEnveda Biosciences mines the chemistry of plants and other natural sources to find new small-molecule medicines, combining metabolomics, machine learning, automation and biological assays. Founded in 2019 and based in Boulder, Colorado, the company built a biologically annotated database of plant chemistry to guide its drug discovery.
Its AI model, MS2Mol, predicts the chemical structure of metabolites directly from mass spectrometry data, letting scientists identify new drug candidates without lengthy lab work, and the company uses Bruker's timsTOF instruments to analyze complex natural samples at scale.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Enveda Biosciences.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Enveda Biosciences availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Enveda Biosciences included.
The last valuation is $650M.
Lead investors for each round are in the funding timeline.
The closest ai drug discovery peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Enveda Biosciences is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
